SCHEMBL6090937

SCHEMBL6090937

O=C(O)CCNc1ccccc1Br

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
HPGD P15428 2/20 0.64
HSD17B10 Q99714 2/20 0.64
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
RXFP1 Q9HBX9 2/20 0.54
NSD2 O96028 1/20 0.54
POLB P06746 1/20 0.54
BLM P54132 1/20 0.54
L3MBTL1 Q9Y468 3/20 0.53
APEX1 P27695 1/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPT P10636 1/20 0.53
AKR1C3 P42330 1/20 0.53
AKR1C2 P52895 1/20 0.53
AKR1C1 Q04828 1/20 0.53
LMNA P02545 3/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 2/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29577048 1.00 ALDH1A1 (0.64) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL28326425 0.84 ALDH1A1 (0.45) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL12533712 0.83 ALDH1A1 (0.53) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL31746636 0.83 ALDH1A1 (0.53) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL31584089 0.83 ALDH1A1 (0.53) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL31393673 0.83 ALDH1A1 (0.53) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL158269 0.81 KMT2A (0.50) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL29864421 0.81 KMT2A (0.50) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL29136436 0.81 ALDH1A1 (0.44) ALDH1A1HPGDHSD17B10KMT2APOLB
SCHEMBL3207752 0.79 ALDH1A1 (0.66) ALDH1A1HPGDHSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313561-A1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2025-10-09 US disclosed
US-12344606-B2 Next-generation modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2025-07-01 US disclosed
US-20240352021-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2024-10-24 US disclosed
EP-4419529-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2024-08-28 EP disclosed
CN-117120440-A TYK2 inhibitor and application thereof 苏多生物科学有限公司 2023-11-24 CN disclosed
EP-3983078-B1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2023-11-15 EP disclosed
EP-3983078-B1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2023-11-15 EP disclosed
WO-2023069959-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-04-27 WO disclosed
US-20220251082-A1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-08-11 US disclosed
EP-3983078-A1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-04-20 EP disclosed
WO-2020249773-A1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2020-12-17 WO disclosed
WO-2020249773-A1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2020-12-17 WO disclosed
CN-109503478-B 2, 3-dihydro-1H-quinoline-4-ketone thiosemicarbazone derivative and preparation method and application thereof 岭南师范学院 2020-04-24 CN disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
CN-109503478-A 2,3- dihydro -1H- quinolin-4-one thiosemicarbazone derivative and its preparation method and application 岭南师范学院 2019-03-22 CN disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed
US-20090197856-A1 ANTIVIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2009-08-06 US disclosed
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 ALDH1A1 1890/4885HPGD 1459/4885HSD17B10 2104/4885
US-20220251082-A1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS ALDH1A1 4562/4885HPGD 312/4885HSD17B10 3973/4885
US-12344606-B2 Next-generation modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS ALDH1A1 4562/4885HPGD 312/4885HSD17B10 3973/4885
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS ALDH1A1 3241/4885HPGD 3135/4885HSD17B10 1740/4885
US-20090197856-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, EIF2AK2, MAVS ALDH1A1 2216/4885HPGD 3520/4885HSD17B10 1840/4885
US-20240352021-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB3 ALDH1A1 2865/4885HPGD 1650/4885HSD17B10 3418/4885
US-20250313561-A1 NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS ALDH1A1 4562/4885HPGD 312/4885HSD17B10 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.